| Latest | F'cast | |
|---|---|---|
| Div Yield | 2.7% | |
| Div Cover | 1.5 | |
| Op Mrgn | 24.7% | |
| ROCE | 40.2% |
| Latest | F'cast | |
|---|---|---|
| P/E | 24.9 | |
| PEG | 0.3 | |
| Pr/Revenue | 5.2 | |
| Pr/Book | 22.2 |
| Latest | F'cast | |
|---|---|---|
| Revenue | 10.0% | |
| PBT | 94.7% | |
| EPS | 88.1% | |
| DPS | 5.8% |
| Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-21 | 25,979.00 | 6,701.00 | 1,034.00¢ | 21.8 | n/a | -17% | 722.00¢ | 3.2% |
| 31-Dec-22 | 26,323.00 | 7,346.00 | 1,218.00¢ | 21.6 | 1.2 | +18% | 795.00¢ | 3.0% |
| 31-Dec-23 | 28,190.00 | 7,855.00 | 1,256.00¢ | 22.9 | 7.6 | +3% | 864.00¢ | 3.0% |
| 31-Dec-24 | 33,424.00 | 4,609.00 | 762.00¢ | 34.2 | n/a | -39% | 913.00¢ | 3.5% |
| 31-Dec-25 | 36,751.00 | 8,976.00 | 1,433.00¢ | 22.8 | 0.3 | +88% | 966.00¢ | 3.0% |
| Year Ending | Revenue ($m) | Pre-tax ($m) | EPS | P/E | PEG | EPS Grth. | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 31-Dec-26 | 37,762.83 | 16,503.73 | 2,239.27¢ | 16.1 | 0.3 | +56% | 1,024.20¢ | 0.0% |
| 31-Dec-27 | 38,698.60 | 16,942.48 | 2,345.40¢ | 15.4 | 3.2 | +5% | 1,082.22¢ | 0.0% |
Copyright © 2026 FactSet Research Systems Inc. All rights reserved.
| SEP cashes in as US giant Amgen buys cancer drug... | 26-Jan-2011 | The Scotsman |
| Amgen Buys a Cancer Drug Maker | 25-Jan-2011 | New York Times |
| Tech Ticker | 16-Dec-2010 | BayArea.com |
| Currency | US Dollars |
| Share Price | $ 373.51 |
| Change Today | $ 12.18 |
| % Change | 3.37 % |
| 52 Week High | $387.62 |
| 52 Week Low | $271.18 |
| Volume | 467,496 |
| Shares Issued | 538.80m |
| Market Cap | $201,244m |
| Beta | 0.02 |
| RiskGrade | 100 |
| Strong Buy | 5 |
| Buy | 7 |
| Neutral | 15 |
| Sell | 2 |
| Strong Sell | 1 |
| Total | 30 |

| Time | Volume / Share Price |
| 11:30 | 100 @ $373.57 |
| 11:30 | 40 @ $373.51 |
| 11:30 | 40 @ $373.51 |
| 11:30 | 40 @ $373.51 |
| 11:30 | 42 @ $373.56 |
You are here: research